Patents Examined by Benjamin J Packard
  • Long-acting polymeric delivery systems
    Patent number: 11413350
    Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: August 16, 2022
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Skeletal removal of bisphosphonates
    Patent number: 11400104
    Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 2, 2022
    Assignees: The Regents of the University of California, BioVinc LLC, University of Southern California
    Inventors: Frank Hallock Ebetino, Ichiro Nishimura, Shuting Sun, Mark Walden Lundy, Akishige Hokugo, Charles McKenna, Keivan Sadrerafi
  • Insecticide composition
    Patent number: 11382329
    Abstract: The present invention pertains to an insecticide composition containing 2-fluoro-3-(N-methylbenzamide)-N-(2-bromo-6-trifluoromethyl-4-(heptafluoropropane-2-yl)phenyl)benzamide and a solubilizer having a c log P of 0.1-2.1.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 12, 2022
    Assignee: MITSUI CHEMICALS AGRO, INC.
    Inventors: Ayaka Miki, Shingo Nakano, Hideo Tateishi
  • Apomorphine-palmitic acid cocrystal solid particle crystalline form
    Patent number: 11382867
    Abstract: A pharmaceutical composition comprising apomorphine (APO) in a solid crystalline form, wherein the solid crystalline form is an APO·palmitic acid cocrystal solid particle crystalline form.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 12, 2022
    Assignee: LEUKOS BIOTECH, S. L.
    Inventors: Enrique Llaudet Carles, Nicolas Tesson, Montserrat Trilla Castaño
  • Process of preparing mRNA-loaded lipid nanoparticles
    Patent number: 11357726
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 14, 2022
    Inventors: Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Goldman, Frank DeRosa, Michael Heartlein
  • Rifabutin treatment methods, uses, and compositions
    Patent number: 11351158
    Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: June 7, 2022
    Assignee: BIOVERSYS AG
    Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
  • Phenylsulfonyl oxazole derivative and use thereof
    Patent number: 11345671
    Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: May 31, 2022
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Jae Sung Bae, Hee Kyung Jin, Myung Shik Lee, Hye Jin Lim, Jin Hee Ahn, Haushabhau Shivaji Pagire, Min Jae Lee
  • Rifabutin treatment methods, uses, and compositions
    Patent number: 11344537
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: May 31, 2022
    Assignee: BIOVERSYS AG
    Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
  • Injectable peripheral nerve specific hydrogel
    Patent number: 11338058
    Abstract: The present invention relates to a peripheral nerve-specific hydrogel material, which is deliverable in a minimally invasive fashion, sustains the growth of neurons, and speeds recovery following surgical reconstruction.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 24, 2022
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, CORNELL UNIVERSITY
    Inventors: Bryan Nicklaus Brown, Jonathan Cheetham
  • Multi-use torasemide composition
    Patent number: 11337921
    Abstract: An aqueous composition including torasemide and at least one organic solvent, to a bottle or container including the composition, and to a kit including the bottle or container and a device for delivery of the composition (for example a syringe). A use of at least one organic solvent for increasing the stability and/or the antimicrobial properties of a composition including torasemide. A method for preparing the composition.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: May 24, 2022
    Assignee: VETOQUINOL SA
    Inventors: Marinette Moreau, Elodie Lego
  • Formulation and process for limiting nerve trauma
    Patent number: 11324758
    Abstract: Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery. In some aspects, disclosed is a formulation for reducing nerve trauma comprising an active pharmacological ingredient adapted to intervene in the activation of pathways of cellular degradation within the nerve and a carrier adapted to reduce dissemination of the active pharmacological ingredient beyond the site at which its effect is intended.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: May 10, 2022
    Assignee: Intravital Pty Ltd
    Inventors: Timothy J. Eviston, Arun Krishnan
  • Diversion-resistant opioid formulations
    Patent number: 11318132
    Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: May 3, 2022
    Assignee: Elysium Therapeutics, Inc.
    Inventor: Thomas E. Jenkins
  • Programmable polymeric drugs
    Patent number: 11312736
    Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: April 26, 2022
    Assignee: Sony Corporation
    Inventors: Tracy Matray, Sharat Singh, C. Frederick Battrell, Michael Vanbrunt
  • Treatment methods for medical and dental implants, periodontal diseases and medical procedures
    Patent number: 11311463
    Abstract: Dental and medical treatments and methods, including treating gum disease, using peroxide gel and a viscous antimicrobial including a topical antibacterial agent, a topical antiviral agent, a topical antibiotic, a topical antifungal agent, a topical antiseptic agent, or a topical anti-intermicrobial agent to chemically debride and curettage a treatment area. Treatments and methods include non-surgically scaling and root plaining the treatment area with dental tools such as periodontal scalers and/or curettes during the active period of the chemical debridement. The working surfaces of dental and medical tools can be sharpened for optimal root and tooth surfacing during treatment. Treatment can include instructions for co-therapy by or on behalf of treatment subjects between visits and for maintenance care.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: April 26, 2022
    Inventor: Larry P. Bleier
  • DNA-templated micelle and uses thereof
    Patent number: 11311629
    Abstract: The present invention discloses a multifunctional DNA-templated micelle system that has a payload carrier of at least a DNA bridge and a functionalized polyethylene glycol (PEG) segment. The micelle can be used to deliver molecules, such as drugs and polynucleotides, to targeted cells for pharmaceutical uses. The PEG segment provides a functional group, such as amine, for ligand conjugation. The DNA-templated micelle of the present invention is highly controllable in size, loading efficiency and tissue targeting, and can carry multiple payloads for targeted combination strategies in cancer therapy, such as gene delivery, gene therapy, and immunotherapy.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 26, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Kam W. Leong, Yeh-Hsing Lao, Tzu-Chieh Ho, Smruthi Suryaprakash
  • Cell penetrating peptide (CPP)-mediated EV loading
    Patent number: 11298319
    Abstract: The present invention relates to methods for loading extracellular vesicles (EVs) with a pharmacological agent. The invention discloses the use of cell-penetrating peptides as carriers into EVs, using either a non-covalent or covalent loading approach. Furthermore, the present invention pertains to medical uses and compositions comprising such pharmacological agent-loaded EVs.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 12, 2022
    Assignee: Evox Therapeutics Ltd
    Inventors: Oscar Wiklander, Per Lundin, Dhanu Gupta
  • Cannabidiol alkaline composition
    Patent number: 11285184
    Abstract: An aqueous alkaline composition comprising a cannabinoid which may be cannabidiol (CBD) used alone or in combination with other cannabinoids. An alkalizing agent which comprises pico size carbon particles is present in the composition, in an amount suitable for buffering the composition to a pH between about 7.5 and 9.5. The aqueous alkaline composition is stable and may be used in the preparation of a beverage or a pharmaceutical composition.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 29, 2022
    Inventor: Sreedhar Cheekoori
  • Compositions for treating joint or connective tissue disease comprising dextran or poloxamer
    Patent number: 11278565
    Abstract: Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: March 22, 2022
    Assignee: MEDICINE PARK CO., LTD.
    Inventors: Yoo Sin Park, Il Hoon Lee
  • Skincare system
    Patent number: 11278747
    Abstract: A system and method may allow a person to rotate a skin care product based on the current climate to help skin transition to and react to changes in temperature and humidity the air. For example, each moisturizer may be formulated to support skin needs for a specific climate, such as tropical climate (i.e., humid and hot air), a desert climate (i.e., dry and hot air), a temperate climate (i.e., normal and mild air), and/or a polar climate (i.e., cold and dry air).
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: March 22, 2022
    Assignee: Pour Moi Beauty, LLC
    Inventor: Ulrike Haslacher
  • Estrogen receptor modulators for treating mutants
    Patent number: 11278532
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: March 22, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate